--- title: "BPC-157: Benefits, Dosage, Side Effects & How It Works" description: "BPC-157 explained: how this stomach-derived peptide works, what it is studied for in tendons, muscle and the gut, side effects, and what to expect." canonical: "https://www.vitalsvault.com/peptides/bpc-157" last-updated: 2026-08-22 --- # BPC-157: Benefits, Dosage, Side Effects & How It Works > BPC-157 explained: how this stomach-derived peptide works, what it is studied for in tendons, muscle and the gut, side effects, and what to expect. ![A Filipina woman, 45, small, tan skin, straight black hair with a few greys in a low ponytail, grey t-shirt, sits on a wooden trailhead bench with…](https://www.vitalsvault.com/_next/image?url=%2Fpublic-v3%2Fshoot%2Fpeptides%2Fpep-bpc157.webp&w=3840&q=75&dpl=shadow-production-f0162cb4d465-40992538108-1) Peptide Guide · Recovery and repair # BPC-157 Body protection compound-157 BPC-157 began as a peptide that protects the stomach lining. Three decades of research later, it is one of the most searched peptides in the US. [Get early access to peptide care](https://www.vitalsvault.com/peptides-waitlist)[Start with 120+ lab tests · $99](https://www.vitalsvault.com/labs#plans) Free to join · One email when peptide care opens · Most lab results in 3–5 business days Studied forTendon, ligament, muscle and gut repair EvidenceEarly research Taken asInjection under the skin or by mouth, as prescribed Studied forTendon, ligament, muscle and gut repair EvidenceEarly research Taken asInjection under the skin or by mouth, as prescribed ## BPC-157, in short BPC-157 (body protection compound-157) is a 15-amino-acid peptide copied from a protective protein in human gastric juice. It is studied for healing tendons, ligaments, muscle and bone and for protecting the gut lining, largely by helping new blood vessels grow into injured tissue. Most evidence comes from animal studies, with early human reports. Medically reviewed by [Robert Lufkin, MD (opens in a new tab)](https://www.robertlufkinmd.com/) Chief Medical Officer, Vitals Vault · Updated October 29, 2026 · 13 sources ## At a glance Early research TypeSynthetic peptide, 15 amino acids (GEPPPGKPADDAGLV)[4](https://www.vitalsvault.com/peptides/bpc-157#source-sikiric-2006) Based onA protective protein in human gastric juice[1](https://www.vitalsvault.com/peptides/bpc-157#source-vasireddi-2025) Studied forTendon, ligament, muscle, bone and gut repair[1](https://www.vitalsvault.com/peptides/bpc-157#source-vasireddi-2025)[2](https://www.vitalsvault.com/peptides/bpc-157#source-gwyer-2019) Taken asInjection under the skin or by mouth, as prescribed Half-lifeUnder 30 minutes; cleared by the liver and kidneys[1](https://www.vitalsvault.com/peptides/bpc-157#source-vasireddi-2025) FDA statusNot approved. 503A compounding allowed since October 29, 2026[10](https://www.vitalsvault.com/peptides/bpc-157#source-ncpa) SportProhibited by WADA[13](https://www.vitalsvault.com/peptides/bpc-157#source-wada) ## Before you consider BPC-157 - Safety No formal human safety trials have been published. Animal studies found no harm across several organ systems, and bad vial quality is a real risk.[1](https://www.vitalsvault.com/peptides/bpc-157#source-vasireddi-2025)[11](https://www.vitalsvault.com/peptides/bpc-157#source-fda-bulks) [Side effects and safety](https://www.vitalsvault.com/peptides/bpc-157#safety) - Legal status Not FDA approved. Since October 29, 2026, 503A pharmacies may compound it for one patient with a prescription.[10](https://www.vitalsvault.com/peptides/bpc-157#source-ncpa) [FDA status](https://www.vitalsvault.com/peptides/bpc-157#fda-status) - How it’s taken Most often an injection under the skin. Some pharmacies make oral capsules, and your prescriber picks the form.[4](https://www.vitalsvault.com/peptides/bpc-157#source-sikiric-2006) [Forms and dosage](https://www.vitalsvault.com/peptides/bpc-157#how-taken) ## How does BPC-157 work? Research points to three actions, all tied to how the body repairs itself. - ### Grows new blood vessels It helps build tiny new blood vessels, so tissue that heals slowly, like tendons, gets more blood.[1](https://www.vitalsvault.com/peptides/bpc-157#source-vasireddi-2025)[4](https://www.vitalsvault.com/peptides/bpc-157#source-sikiric-2006) - ### Helps cells hear repair signals Tendon cells made more of the docks that growth hormone uses, so they respond better to repair signals.[1](https://www.vitalsvault.com/peptides/bpc-157#source-vasireddi-2025) - ### Calms inflammation It lowered the chemical alarms that keep inflammation going, and it protected the lining of blood vessels.[1](https://www.vitalsvault.com/peptides/bpc-157#source-vasireddi-2025)[4](https://www.vitalsvault.com/peptides/bpc-157#source-sikiric-2006) ## BPC-157 benefits: what it is studied for Almost all of this research is in animals. The one human result here is a small report with no comparison group. 1. Animal study01 ### Tendon and ligament healing In rats with fully cut Achilles tendons, BPC-157 helped them heal faster and stronger. Reviews describe consistent healing across tendon and ligament injuries in animals.[3](https://www.vitalsvault.com/peptides/bpc-157#source-staresinic-2003)[2](https://www.vitalsvault.com/peptides/bpc-157#source-gwyer-2019) 2. Animal study02 ### Muscle recovery In animal studies, muscle healed better after direct injury, and BPC-157 protected muscle against some whole-body stresses.[2](https://www.vitalsvault.com/peptides/bpc-157#source-gwyer-2019) 3. Human study03 ### Long-term knee pain In one clinic report, 7 of 12 people with long-term knee pain had relief for over six months after one injection. There was no comparison group.[1](https://www.vitalsvault.com/peptides/bpc-157#source-vasireddi-2025) 4. Animal study04 ### Gut lining protection In animal models, it protected the stomach, esophagus and intestine from injury caused by alcohol and anti-inflammatory painkillers.[4](https://www.vitalsvault.com/peptides/bpc-157#source-sikiric-2006)[9](https://www.vitalsvault.com/peptides/bpc-157#source-sikiric-2013) ## What the research shows Early research 1. 1 · Cells in a lab Studied In a dish, it reversed a toxin’s block on tendon-cell growth, though it did nothing to tendon cells on its own.[3](https://www.vitalsvault.com/peptides/bpc-157#source-staresinic-2003) Shows a mechanism 2. 2 · Animals Studied Cut rat Achilles tendons healed stronger, and 35 of 36 studies in a 2025 review were animal studies that showed better healing.[3](https://www.vitalsvault.com/peptides/bpc-157#source-staresinic-2003)[1](https://www.vitalsvault.com/peptides/bpc-157#source-vasireddi-2025) Shows an effect in a body 3. 3 · PeopleNot yet No controlled human trials yet. One small knee report found relief in 7 of 12 people, with no comparison group.[1](https://www.vitalsvault.com/peptides/bpc-157#source-vasireddi-2025) Shows it works in people The 2025 HSS Journal review is the most complete look at BPC-157 for muscles and joints. Thirty-five of its 36 studies were preclinical, and they consistently showed better healing in muscle, tendon, ligament and bone. Larger controlled human trials are the next step.[1](https://www.vitalsvault.com/peptides/bpc-157#source-vasireddi-2025) The full guide to BPC-157 9 min read · Medically reviewed by Robert Lufkin, MD ## How a stomach peptide ended up in the tendon conversation Ask why a molecule borrowed from stomach juice gets mentioned every time someone tears an Achilles tendon, and you get one of the stranger stories in sports medicine. Your stomach lining lives in acid, gets scraped by food and alcohol every day, and repairs itself constantly. In the early 1990s, researchers in Croatia went looking for what helps it do that, and they found a protective protein in human gastric juice. BPC-157 is a 15-piece fragment of that protein, rebuilt in a lab. Chemists call a chain of 15 amino acids a pentadecapeptide, and this one reads GEPPPGKPADDAGLV. The name stands for body protection compound-157, and its developers point to one trait above the others: it is unusually stable, which is rare for a peptide that has to survive the place it came from. For three decades, BPC-157 lived an odd double life. The science stayed small. A 2025 systematic review searching publications from 1993 onward turned up 544 articles, yet only a handful of research groups have studied it in depth. Meanwhile, its reputation grew far beyond those labs, carried by athletes and online forums. It did set out once on the road to becoming a conventional medicine. Under the codes PL 10, PLD 116 and PL 14736, developed with the Croatian drugmaker Pliva, it entered clinical trials for inflammatory bowel disease, and its developers describe it as safe in those trials. To see why orthopedic researchers took an interest in a gut peptide, you have to follow the blood.[4](https://www.vitalsvault.com/peptides/bpc-157#source-sikiric-2006)[1](https://www.vitalsvault.com/peptides/bpc-157#source-vasireddi-2025)[2](https://www.vitalsvault.com/peptides/bpc-157#source-gwyer-2019) ## How BPC-157 works: roads, receptors and a quieter alarm Healing is a supply problem before it is anything else. A damaged tissue can only rebuild as fast as oxygen, nutrients and repair cells arrive, and they arrive by blood. The most consistent finding in BPC-157 research is that it acts on angiogenesis, the growth of new small blood vessels from existing ones. Picture a building site at the end of a dirt track. You can have the best crew in the world, but nothing gets built until someone paves the road. In the animal research, BPC-157 behaves like a road crew for injured tissue, and the 2025 systematic review describes it acting on the pathways that drive both cell growth and new vessel formation. The second thread is about listening. Growth hormone can only instruct a cell that carries growth hormone receptors on its surface, and BPC-157 increases how many of those receptors cells express. In principle, a tissue with more receptors can hear the same hormone more clearly. The same review reports that BPC-157 lowers inflammatory cytokines, the chemical alarms immune cells use to keep inflammation going. Its developers add a fourth layer: effects on the endothelium, the single sheet of cells lining every blood vessel, and on nitric oxide, the gas that vessel walls use to relax and control blood flow. They also report effects on endothelin, a vessel-tightening signal, and on somatosensory nerves. Read together, these findings describe a peptide that works on the plumbing of repair more than on any one tissue, which is exactly why it turns up in such different places.[1](https://www.vitalsvault.com/peptides/bpc-157#source-vasireddi-2025)[4](https://www.vitalsvault.com/peptides/bpc-157#source-sikiric-2006) ## Why tendons heal slowly, and what the rat studies showed Tendons and ligaments are engineered for strength, and they pay for it with a thin supply line. Compared with muscle, they carry few blood vessels and few cells. That is why a bruised thigh muscle can feel fine in a week while an Achilles or elbow tendon nags for months. Researchers call these tissues hypovascular and hypocellular. In 2003, a team at the University of Zagreb tested BPC-157 on about the hardest version of that problem. They cut rats’ Achilles tendons all the way through and followed healing for two weeks. Treated tendons withstood more load before failing, the rats walked better, and the tissue laid down more collagen. In a dish, BPC-157 did nothing to tendon cells on its own, but it reversed the growth-blocking effect of 4-hydroxynonenal, a toxic by-product of cellular stress. By 2019, enough work had piled up for a review in Cell and Tissue Research. Every study the authors found showed consistently positive, prompt healing, across many soft tissues and across both direct injuries and whole-body insults. They singled out tendon and ligament, the tissues with the poorest blood supply, as where BPC-157 shows the most promise. The same reviewers drew the boundary clearly. Most of the studies were in small rodents, and they wrote that efficacy is yet to be confirmed in humans. Holding both facts at once, a consistent signal and an unfinished case, is the right way to read everything that follows.[3](https://www.vitalsvault.com/peptides/bpc-157#source-staresinic-2003)[2](https://www.vitalsvault.com/peptides/bpc-157#source-gwyer-2019) ## Back where it started: BPC-157 and the gut Because BPC-157 came from gastric juice, its first tests happened at home. When researchers gave it into the stomachs of rats exposed to alcohol, the small blood vessels of the stomach stayed intact, and lesions of the stomach, esophagus and duodenum were held back. It is the same vessel story, told in its original setting. Some of the most surprising findings concern the gut’s valves. The lower esophageal sphincter keeps stomach contents out of the esophagus, and the pyloric sphincter controls how the stomach empties. In rats with long-standing esophagitis, BPC-157 restored pressure in both. Another line of work will interest anyone who reaches for ibuprofen when a knee aches. NSAIDs, the common anti-inflammatory painkillers, can injure the gut lining over time. In experimental models, BPC-157 counteracted gastrointestinal and other damage from NSAIDs. In animal models, then, the same peptide studied for tendon repair also blunted the side effects of the pills people take for tendon pain. Whether that holds in people has not been tested. The gut is also where BPC-157 went furthest in people, through the inflammatory bowel disease trials run under the PL 14736 code. That makes the gut both its birthplace and the place it was tested in people under a formal drug program.[4](https://www.vitalsvault.com/peptides/bpc-157#source-sikiric-2006)[9](https://www.vitalsvault.com/peptides/bpc-157#source-sikiric-2013) ## Muscle, bone and joints: what the 2025 review found The most complete map of BPC-157 for muscles and joints arrived in 2025, in HSS Journal, the research journal of the Hospital for Special Surgery. The authors screened 544 articles and kept 36 that met their standards: 35 preclinical studies and 1 clinical report. Across the preclinical models, BPC-157 improved outcomes after muscle, tendon, ligament and bone injuries, and it did so on three kinds of measure. Functional measures asked whether the animal used the limb better. Structural measures looked at how the healing tissue was organized. Biomechanical measures tested how much load it could take. A tendon that looks tidy under a microscope but tears at light load has not really healed, so improvement on all three is the more convincing pattern. Muscle studies added a twist. The 2019 review describes benefit after direct trauma and after whole-body insults such as hyperkalemia and hypermagnesemia, abnormally high potassium and magnesium levels that disturb how muscle fires. Benefit in both settings hints that it acts on something more general than one wound. The single clinical report in the review involved knees: 7 of 12 people with long-term knee pain reported relief lasting more than six months after one injection into the joint. Hold on to that number. It is small and uncontrolled, but it raises the most interesting question about BPC-157.[1](https://www.vitalsvault.com/peptides/bpc-157#source-vasireddi-2025)[2](https://www.vitalsvault.com/peptides/bpc-157#source-gwyer-2019) ## Gone in 30 minutes, felt for months BPC-157 has a half-life of less than 30 minutes. The liver breaks it down and the kidneys clear it, so, at least on that measure, it does not linger in the bloodstream for long. Yet in the knee report, people described relief that lasted more than six months after a single dose. One way to reconcile those two facts is that BPC-157 behaves less like a supplement that has to stay in your system and more like a starter signal. The mechanism research is at least consistent with that idea. Building new small vessels, raising growth hormone receptor levels and quieting inflammation are all changes a tissue could carry forward after the peptide itself is gone. This is a hypothesis, not a proven explanation. The knee report had no comparison group, so natural recovery or a placebo response could explain some of the relief, and nobody has measured this sequence in people. But it is the right lens for thinking about BPC-157, and it changes the practical question from how much of it you can keep in your blood to whether your tissue has what it needs to rebuild once the signal is sent: blood supply, protein, sleep and sensible loading.[1](https://www.vitalsvault.com/peptides/bpc-157#source-vasireddi-2025) Know your baseline before any peptide 120+ lab tests at Quest Diagnostics, every result reviewed by a licensed clinician. Most results in 3–5 business days. A baseline today gives your clinician something to compare against if you start BPC-157 later. [Start with 120+ lab tests · $99](https://www.vitalsvault.com/labs#plans)[Get early access to peptide care](https://www.vitalsvault.com/peptides-waitlist) Full refund before your blood draw · No membership ## What we actually know in people The human record is short enough to describe in full. There are the inflammatory bowel disease trials in Croatia, which its developers describe as safe. And there is the 12-person knee report, the only clinical study among the 36 in the 2025 systematic review. That leaves a real gap between a consistent animal signal and proven benefit in people. The 2019 reviewers said so plainly, the 2025 review found no clinical safety data, and with only a handful of research groups involved, independent replication is still thin. None of that cancels the reasons for interest. The animal results point the same way across tissues, injury types and three decades of work. If you and a clinician decide to try it, a careful, measured approach makes sense, which is what the next two sections are about.[1](https://www.vitalsvault.com/peptides/bpc-157#source-vasireddi-2025)[2](https://www.vitalsvault.com/peptides/bpc-157#source-gwyer-2019)[4](https://www.vitalsvault.com/peptides/bpc-157#source-sikiric-2006) ## Safety, side effects and the quality problem In animals, the safety record is reassuring. Preclinical safety studies found no adverse effects across several organ systems, and the 2019 review noted that few studies report adverse reactions at all. That matches what its developers report from the bowel disease trials. The unknowns are about people and about time. The 2025 review found no clinical safety data, so long-term effects in humans have not been measured. FDA’s April 2026 compounding safety page made the same point in regulatory language, noting little or no safety information for the proposed routes. One practical risk is easy to overlook: the vial itself. The 2025 review lists unregulated manufacturing and contamination alongside unknown clinical safety. A peptide is only as clean as the facility that made it, which is why a prescription filled by a licensed compounding pharmacy is a different thing from a vial bought online. Some people should talk with a clinician before considering it: anyone with liver or kidney disease, given how it is cleared; anyone pregnant or breastfeeding; anyone with a history of cancer, because it encourages new blood vessel growth; and tested athletes.[1](https://www.vitalsvault.com/peptides/bpc-157#source-vasireddi-2025)[2](https://www.vitalsvault.com/peptides/bpc-157#source-gwyer-2019)[11](https://www.vitalsvault.com/peptides/bpc-157#source-fda-bulks)[4](https://www.vitalsvault.com/peptides/bpc-157#source-sikiric-2006) ## How labs turn a guess into an experiment Because BPC-157 is processed by the liver and cleared by the kidneys, those are the two organs worth checking before you start and after you finish. ALT, alanine aminotransferase, is an enzyme that leaks into the blood when liver cells are stressed, so a clear rise from your own baseline is worth reviewing with your clinician. eGFR, the estimated glomerular filtration rate, shows how well your kidneys filter. hs-CRP, high-sensitivity C-reactive protein, is made by the liver in response to inflammation anywhere in the body. It is not a BPC-157 test, but since so much of the BPC-157 story is about inflammation, a baseline gives your clinician general context, and a retest shows how your overall inflammation has moved. This is how Vitals Vault approaches peptide care. A blood panel at Quest Diagnostics comes first, a licensed clinician reviews your results and history and decides whether BPC-157 fits, and the course ends with a retest of the same markers. The clinician sets the form and length of the course.[1](https://www.vitalsvault.com/peptides/bpc-157#source-vasireddi-2025) ## Where BPC-157 stands in 2026 On October 29, 2026, NCPA reported that FDA granted enforcement discretion allowing 503A compounding pharmacies to prepare BPC-157, and five other peptides, for individual patients with a prescription. There is no end date, and final rulemaking is still pending. BPC-157 is still not an FDA-approved drug, which means no company has put it through the trials an approval requires. Athletes play by a separate rulebook. The World Anti-Doping Agency’s 2026 Prohibited List names BPC-157 under S0, non-approved substances, so anyone in tested sport, amateur or professional, should treat it as banned.[10](https://www.vitalsvault.com/peptides/bpc-157#source-ncpa)[11](https://www.vitalsvault.com/peptides/bpc-157#source-fda-bulks)[13](https://www.vitalsvault.com/peptides/bpc-157#source-wada) ## What this means for you BPC-157 is a small, stable fragment of the stomach’s own repair kit that, across three decades of animal research, consistently helps damaged tissue rebuild, with its strongest promise in the slow-healing tissues that frustrate people most. Its human evidence is early, its safety in people is under-measured, and its quality depends on who made it. If you are considering it, the most useful question is not whether BPC-157 works in general. It is what is slowing your healing right now, and whether a better blood supply would change that. A clinician, your history and a before-and-after blood panel are how you find out.[2](https://www.vitalsvault.com/peptides/bpc-157#source-gwyer-2019)[1](https://www.vitalsvault.com/peptides/bpc-157#source-vasireddi-2025) Know your baseline before any peptide 120+ lab tests at Quest Diagnostics, every result reviewed by a licensed clinician. Most results in 3–5 business days. A baseline today gives your clinician something to compare against if you start BPC-157 later. [Start with 120+ lab tests · $99](https://www.vitalsvault.com/labs#plans)[Get early access to peptide care](https://www.vitalsvault.com/peptides-waitlist) Full refund before your blood draw · No membership ## What to expect with BPC-157 A responsible start looks like this: a health history, a baseline blood panel and a clinician’s decision on whether BPC-157 fits your situation and in what form. The course length is set by the prescriber, and it ends with a retest of the same markers. On timing, the human evidence is limited to one signal worth knowing. In the knee report, the people who improved described relief lasting more than six months after a single injection. That fits the idea that BPC-157 works as a starting signal, so what you do alongside it, from rehab to sleep, matters as much as the peptide itself.[1](https://www.vitalsvault.com/peptides/bpc-157#source-vasireddi-2025) ## Key BPC-157 studies - Staresinic et al., 2003[3](https://www.vitalsvault.com/peptides/bpc-157#source-staresinic-2003) Animal study · Rats with fully cut Achilles tendons Stronger, better-functioning tendons with more collagen by day 14; in a dish, it reversed a toxin’s block on tendon-cell growth Limits: Rats, not people - Sikiric et al., 2006[4](https://www.vitalsvault.com/peptides/bpc-157#source-sikiric-2006) Review of the developers’ program · Animal models; IBD trials as PL 14736 Protected the stomach, esophagus and duodenum; described as safe in IBD trials Limits: Written by the developers; trial data not published in full - Sikiric et al., 2013[9](https://www.vitalsvault.com/peptides/bpc-157#source-sikiric-2013) Review of experimental studies · Animal models Counteracted gut and other damage from NSAID painkillers Limits: Experimental models only - Gwyer et al., 2019[2](https://www.vitalsvault.com/peptides/bpc-157#source-gwyer-2019) Narrative review · Mostly small rodents Consistent, prompt healing across soft tissues; most promise in tendon and ligament Limits: Efficacy not yet confirmed in humans - Vasireddi et al., 2025[1](https://www.vitalsvault.com/peptides/bpc-157#source-vasireddi-2025) Systematic review, 36 studies · 35 preclinical studies, 1 clinical report Better function, structure and strength after muscle, tendon, ligament and bone injury Limits: No clinical safety data found - Knee pain report (in Vasireddi 2025)[1](https://www.vitalsvault.com/peptides/bpc-157#source-vasireddi-2025) Retrospective case series · 12 adults with chronic knee pain 7 of 12 reported relief lasting over six months after one joint injection Limits: No control group; small Key studies on BPC-157 | Study | Design | Who | What it found | Limits | | --- | --- | --- | --- | --- | | Staresinic et al., 2003[3](https://www.vitalsvault.com/peptides/bpc-157#source-staresinic-2003) | Animal study | Rats with fully cut Achilles tendons | Stronger, better-functioning tendons with more collagen by day 14; in a dish, it reversed a toxin’s block on tendon-cell growth | Rats, not people | | Sikiric et al., 2006[4](https://www.vitalsvault.com/peptides/bpc-157#source-sikiric-2006) | Review of the developers’ program | Animal models; IBD trials as PL 14736 | Protected the stomach, esophagus and duodenum; described as safe in IBD trials | Written by the developers; trial data not published in full | | Sikiric et al., 2013[9](https://www.vitalsvault.com/peptides/bpc-157#source-sikiric-2013) | Review of experimental studies | Animal models | Counteracted gut and other damage from NSAID painkillers | Experimental models only | | Gwyer et al., 2019[2](https://www.vitalsvault.com/peptides/bpc-157#source-gwyer-2019) | Narrative review | Mostly small rodents | Consistent, prompt healing across soft tissues; most promise in tendon and ligament | Efficacy not yet confirmed in humans | | Vasireddi et al., 2025[1](https://www.vitalsvault.com/peptides/bpc-157#source-vasireddi-2025) | Systematic review, 36 studies | 35 preclinical studies, 1 clinical report | Better function, structure and strength after muscle, tendon, ligament and bone injury | No clinical safety data found | | Knee pain report (in Vasireddi 2025)[1](https://www.vitalsvault.com/peptides/bpc-157#source-vasireddi-2025) | Retrospective case series | 12 adults with chronic knee pain | 7 of 12 reported relief lasting over six months after one joint injection | No control group; small | ## BPC-157 myths and evidence - ### Peptides like BPC-157 can’t work by mouth because the stomach destroys them Most peptides are broken down in the gut, but BPC-157 comes from gastric juice and its developers stress its unusual stability. In rat studies it was given directly into the stomach and still protected the gut lining.[4](https://www.vitalsvault.com/peptides/bpc-157#source-sikiric-2006) - ### BPC-157 has never been tested in humans It has been, in a limited way. It entered inflammatory bowel disease trials in Croatia under the code PL 14736, and a 12-person knee report is included in the 2025 systematic review. What is missing is large, controlled trials.[4](https://www.vitalsvault.com/peptides/bpc-157#source-sikiric-2006)[1](https://www.vitalsvault.com/peptides/bpc-157#source-vasireddi-2025) - ### BPC-157 causes cancer No study cited here links BPC-157 to cancer. The concern is theoretical: it encourages new blood vessel growth, which tumors also use. Animal safety studies found no harm across several organ systems, but long-term human data do not exist, so people with a cancer history should talk to a clinician first.[1](https://www.vitalsvault.com/peptides/bpc-157#source-vasireddi-2025) - ### A peptide that leaves the blood in 30 minutes can’t do anything Its half-life is under 30 minutes, yet the studied effects outlast it. One plausible reason is that it acts as a signal, prompting new vessels and more growth hormone receptors that remain after the peptide has gone.[1](https://www.vitalsvault.com/peptides/bpc-157#source-vasireddi-2025) Know your baseline first 120+ lab tests at Quest, every result reviewed by a licensed clinician. Most results in 3–5 business days. [Start with 120+ lab tests · $99](https://www.vitalsvault.com/labs#plans) ## How is BPC-157 taken? Compounded BPC-157 is most often prepared as an injection under the skin. Because it survives stomach acid, some pharmacies also make oral capsules, which is the form usually discussed for gut goals. Your prescriber chooses the form, dose and length of a course.[4](https://www.vitalsvault.com/peptides/bpc-157#source-sikiric-2006) ## BPC-157 dosage There is no FDA-approved dose of BPC-157. A handful of small human studies gave it as an enema for ulcerative colitis, as one or two injections into the knee joint, as injections into the bladder wall during a single procedure, and as two infusions into a vein on consecutive days; FDA listed those amounts in its July 2026 review, and the table shows them. No published human study tested the injection under the skin that clinics most often prescribe, and online dosing charts are not based on controlled human trials. Your clinician sets your dose.[8](https://www.vitalsvault.com/peptides/bpc-157#source-fda-pcac-bpc157) ## Typical BPC-157 dosage BPC-157 has no FDA-labelled dose. The human doses on record come from a few small studies: enemas in healthy volunteers and in adults with ulcerative colitis, one or two injections into the knee joint, bladder-wall injections during a single procedure, and a two-person safety pilot of infusions into a vein on two consecutive days. None tested the injection under the skin that clinics most often prescribe, so your clinician sets the actual dose, form and length of use. These are reference doses from FDA labels, studies in people and clinical practice reports, shown for education. They are not a recommendation or a prescription. Your dose, form and schedule should be set by a licensed clinician who knows your history and lab results. Already have a prescribed dose? The [peptide dosage calculator](https://www.vitalsvault.com/peptides/tools/dosage-calculator) turns it into the units to draw on an insulin syringe. - Human trial · Enema (into the rectum) 80 mg Once daily for 2 weeks[8](https://www.vitalsvault.com/peptides/bpc-157#source-fda-pcac-bpc157) Adults with mild to moderate ulcerative colitis; placebo-controlled trial published only as a meeting abstract, as summarized by FDA - Human trial · Enema (into the rectum) 0.25, 0.5, 1 or 2 mg/kg One dose, then once daily for 7 days after a one-week break[8](https://www.vitalsvault.com/peptides/bpc-157#source-fda-pcac-bpc157) Healthy volunteers in a phase 1 tolerability study (meeting abstracts), as summarized by FDA - Clinical practice report · Injection into the knee joint 2 to 4 mg 1 or 2 injections[5](https://www.vitalsvault.com/peptides/bpc-157#source-lee-2021)[8](https://www.vitalsvault.com/peptides/bpc-157#source-fda-pcac-bpc157) Adults with knee pain; BPC-157 alone in 12 patients and combined with thymosin beta-4 in 4; retrospective chart review at one clinic, with no control group - Human trial · Injection into the bladder wall during cystoscopy 10 mg in total (1 mg at each of 10 sites) Once, in a single procedure[6](https://www.vitalsvault.com/peptides/bpc-157#source-lee-2024)[8](https://www.vitalsvault.com/peptides/bpc-157#source-fda-pcac-bpc157) 12 women aged 39 to 76 with moderate to severe interstitial cystitis that had not responded to pentosan polysulfate; pilot study with no control group - Human trial · Infusion into a vein over 1 hour 10 mg on day 1, then 20 mg on day 2 Two infusions on consecutive days[7](https://www.vitalsvault.com/peptides/bpc-157#source-lee-2025)[8](https://www.vitalsvault.com/peptides/bpc-157#source-fda-pcac-bpc157) Safety pilot in 2 healthy adults aged 58 and 68, both of whom had received intravenous BPC-157 before Typical BPC-157 doses in people, by source | Source | Form | Amount | How often | Notes | | --- | --- | --- | --- | --- | | Human trial[8](https://www.vitalsvault.com/peptides/bpc-157#source-fda-pcac-bpc157) | Enema (into the rectum) | 80 mg | Once daily for 2 weeks | Adults with mild to moderate ulcerative colitis; placebo-controlled trial published only as a meeting abstract, as summarized by FDA | | Human trial[8](https://www.vitalsvault.com/peptides/bpc-157#source-fda-pcac-bpc157) | Enema (into the rectum) | 0.25, 0.5, 1 or 2 mg/kg | One dose, then once daily for 7 days after a one-week break | Healthy volunteers in a phase 1 tolerability study (meeting abstracts), as summarized by FDA | | Clinical practice report[5](https://www.vitalsvault.com/peptides/bpc-157#source-lee-2021)[8](https://www.vitalsvault.com/peptides/bpc-157#source-fda-pcac-bpc157) | Injection into the knee joint | 2 to 4 mg | 1 or 2 injections | Adults with knee pain; BPC-157 alone in 12 patients and combined with thymosin beta-4 in 4; retrospective chart review at one clinic, with no control group | | Human trial[6](https://www.vitalsvault.com/peptides/bpc-157#source-lee-2024)[8](https://www.vitalsvault.com/peptides/bpc-157#source-fda-pcac-bpc157) | Injection into the bladder wall during cystoscopy | 10 mg in total (1 mg at each of 10 sites) | Once, in a single procedure | 12 women aged 39 to 76 with moderate to severe interstitial cystitis that had not responded to pentosan polysulfate; pilot study with no control group | | Human trial[7](https://www.vitalsvault.com/peptides/bpc-157#source-lee-2025)[8](https://www.vitalsvault.com/peptides/bpc-157#source-fda-pcac-bpc157) | Infusion into a vein over 1 hour | 10 mg on day 1, then 20 mg on day 2 | Two infusions on consecutive days | Safety pilot in 2 healthy adults aged 58 and 68, both of whom had received intravenous BPC-157 before | ## Is BPC-157 right for you? A clinician makes the call. These are the questions they will ask first. ### It may suit - Adults with a slow-healing tendon, ligament or muscle injury who want a supervised option alongside rehab - People exploring gut-lining support with a clinician - Anyone who wants labs before and after, not guesswork ### Talk to a clinician first if you are - A personal history of cancer - Tested athletes (WADA prohibits it) - Pregnant or breastfeeding - Living with kidney or liver disease Vitals Vault peptide care starts with a blood panel and a licensed clinician, and ends with a retest. [Get early access to peptide care](https://www.vitalsvault.com/peptides-waitlist) ## BPC-157 vs TB-500 [Full comparison](https://www.vitalsvault.com/peptides/bpc-157-vs-tb-500) BPC-157 vs TB-500 | Attribute | BPC-157 | TB-500 | | --- | --- | --- | | Comes from | A gastric juice protein | Thymosin beta-4, a repair protein | | Main action studied | New blood vessels, growth signals | Cell movement, new blood vessels | | Best known for | Tendon, ligament and gut repair | Wound, eye and heart repair | | Usual form | Injection or oral | Injection | ## Blood supply is the bottleneck Tendons and ligaments heal slowly for a structural reason. They have few blood vessels and few cells, so nutrients and repair cells arrive in a trickle. A peptide cannot replace what the tissue needs to rebuild. The reviews point to blood supply, protein, sleep and sensible loading as the things that matter alongside it.[2](https://www.vitalsvault.com/peptides/bpc-157#source-gwyer-2019)[4](https://www.vitalsvault.com/peptides/bpc-157#source-sikiric-2006) ### What else moves the same system 1. 01Load the tissueKeep up pain-guided rehab. Do not let a peptide replace it. 2. 02Eat enough proteinHealing tissue needs building materials. Protein intake is easy to check and easy to fix. 3. 03Protect your sleepSleep is part of the repair routine, so guard it while an injury heals. 4. 04Watch inflammationA high hs-CRP means your whole body is inflamed, which can get in the way of healing. ## Labs to check with BPC-157 A blood test before you start and a retest after shows what actually changed for you. It is how Vitals Vault approaches every treatment. 1. TestA baseline panel at Quest Diagnostics. 2. DecideA licensed clinician reviews your history and results. 3. RetestThe same markers again, side by side. [Start with 120+ lab tests · $99](https://www.vitalsvault.com/labs#plans) - [Liver enzymes (ALT)Part of a metabolic panel. Checks the liver before and during any new prescription.](https://www.vitalsvault.com/biomarkers/alt) - [Kidney function (eGFR)Peptides are cleared through the kidneys, so a baseline is useful.](https://www.vitalsvault.com/biomarkers/egfr) - [hs-CRPA blood marker of inflammation you can track before and after a course.](https://www.vitalsvault.com/biomarkers/hs-crp) ## Is BPC-157 FDA approved? No. Since October 29, 2026, FDA allows 503A pharmacies to compound BPC-157 for individual patients with a prescription, under enforcement discretion, while the final rule is pending.[10](https://www.vitalsvault.com/peptides/bpc-157#source-ncpa) [What FDA’s decision means](https://www.vitalsvault.com/peptides/fda-peptide-compounding-2026) ### BPC-157 timeline 1. 1993 First published research on BPC-157 from the University of Zagreb.[1](https://www.vitalsvault.com/peptides/bpc-157#source-vasireddi-2025) 2. 2003 Rat Achilles tendon study shows faster, stronger healing.[3](https://www.vitalsvault.com/peptides/bpc-157#source-staresinic-2003) 3. 2000s Early clinical trials for inflammatory bowel disease in Croatia (PL 14736).[4](https://www.vitalsvault.com/peptides/bpc-157#source-sikiric-2006) 4. 2025 HSS Journal systematic review of 36 studies in sports medicine.[1](https://www.vitalsvault.com/peptides/bpc-157#source-vasireddi-2025) 5. April 2026 FDA’s compounding safety page lists BPC-157 as a nominated bulk substance and notes how little human safety data exists.[11](https://www.vitalsvault.com/peptides/bpc-157#source-fda-bulks) 6. July 2026 FDA’s Pharmacy Compounding Advisory Committee votes to recommend adding BPC-157 to the 503A bulks list.[10](https://www.vitalsvault.com/peptides/bpc-157#source-ncpa) 7. October 29, 2026 FDA grants enforcement discretion, so 503A pharmacies can compound BPC-157 with a prescription. No end date; final rule pending.[10](https://www.vitalsvault.com/peptides/bpc-157#source-ncpa) ![An Indigenous man, 45, stocky, long black hair tied back, silver ring stands on a pier, looking out](https://www.vitalsvault.com/_next/image?url=%2Fpublic-v3%2Fshoot%2Fpeptides%2Ffaq-bpc157.webp&w=3840&q=75&dpl=shadow-production-f0162cb4d465-40992538108-1) ## BPC-157 questions What is BPC-157 used for? BPC-157 is studied for healing tendons, ligaments, muscle and bone, and for protecting the gut lining. People most often ask about it for sports injuries, joint pain and gut health. It is not FDA-approved to treat any condition. What are the benefits of BPC-157? In research, BPC-157 sped up tendon and ligament healing, improved muscle and bone repair, protected the stomach and intestine from injury, and promoted new blood vessel growth. Most of this evidence comes from laboratory and animal studies. How does BPC-157 work? It builds new blood vessels in injured tissue, raises growth hormone receptor levels in tendon cells, and lowers inflammatory signals. Together these support the body’s own repair process. What are the side effects of BPC-157? Studies report few adverse reactions, but formal human safety trials have not been published. The main practical risk is poor product quality from unregulated sellers. People with a history of cancer should talk to a clinician first. What is the BPC-157 dosage? There is no FDA-approved dose. Small human studies gave BPC-157 as an enema, as one or two injections into the knee joint, as bladder-wall injections in a single procedure, and as two infusions into a vein on consecutive days, and those study amounts are in the dosage table on this page. No published human study tested the injection under the skin most clinics prescribe. Your clinician sets your dose. Is BPC-157 better as an injection or a pill? Injections are the most common compounded form. BPC-157 is unusually stable in stomach acid, so oral capsules exist and are usually discussed for gut goals. Your prescriber decides which fits. Is BPC-157 FDA approved? No. BPC-157 is not FDA-approved for any use. Since October 29, 2026, FDA allows 503A compounding pharmacies to prepare it for individual patients with a prescription, under enforcement discretion, while final rulemaking is pending. Is BPC-157 legal in the US? A licensed prescriber can now order compounded BPC-157 from a 503A pharmacy for a specific patient. Vials sold online as "research use only" are not made for people and are not covered by FDA’s October 2026 policy. Is BPC-157 banned in sports? Yes. The World Anti-Doping Agency lists BPC-157 as a prohibited substance, in and out of competition. Can I get BPC-157 through Vitals Vault? Vitals Vault is opening clinician-led peptide care that starts with a blood test. Join the peptides waitlist to hear first. A licensed clinician reviews your history and labs and decides whether BPC-157 is right for you. ## Peptides, prescribed and measured Vitals Vault is opening peptide care that starts with your blood work, is prescribed by licensed US clinicians and ends with a retest. Join the waitlist to hear first. - Prescription only - Licensed US clinicians - Quest Diagnostics labs [Get early access to peptide care](https://www.vitalsvault.com/peptides-waitlist)[Start with 120+ lab tests · $99](https://www.vitalsvault.com/labs#plans) ## Keep reading [Full Peptide Guide](https://www.vitalsvault.com/peptides) - TB-500A seven-amino-acid piece of thymosin beta-4, the repair protein studied for wounds, eyes and the heart. - BPC-157 vs TB-500How the two most popular recovery peptides differ, and why people take them together. - KPVA three-amino-acid piece of the hormone alpha-MSH, studied for calming gut and skin inflammation. - FDA peptide update 2026What FDA’s October 2026 decision on six peptides means for you. - Thymosin beta-4The full 43-amino-acid repair protein behind TB-500, tested in eye, skin and heart trials. ## Sources 1. 1. [Vasireddi N, et al. Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. HSS J. 2025 (opens in a new tab)](https://pubmed.ncbi.nlm.nih.gov/40756949/) 2. 2. [Gwyer D, et al. BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell Tissue Res. 2019 (opens in a new tab)](https://pubmed.ncbi.nlm.nih.gov/30915550/) 3. 3. [Staresinic M, et al. BPC 157 accelerates healing of transected rat Achilles tendon. J Orthop Res. 2003 (opens in a new tab)](https://pubmed.ncbi.nlm.nih.gov/14554208/) 4. 4. [Sikiric P, et al. Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease (PL 14736). Inflammopharmacology. 2006 (opens in a new tab)](https://pubmed.ncbi.nlm.nih.gov/17186181/) 5. 5. [Lee E, Padgett B. Intra-articular injection of BPC 157 for multiple types of knee pain. Altern Ther Health Med. 2021 (opens in a new tab)](https://pubmed.ncbi.nlm.nih.gov/34324435/) 6. 6. [Lee E, et al. Effect of BPC-157 on symptoms in patients with interstitial cystitis: a pilot study. Altern Ther Health Med. 2024 (opens in a new tab)](https://pubmed.ncbi.nlm.nih.gov/39325560/) 7. 7. [Lee E, Burgess K. Safety of intravenous infusion of BPC157 in humans: a pilot study. Altern Ther Health Med. 2025 (opens in a new tab)](https://pubmed.ncbi.nlm.nih.gov/40131143/) 8. 8. [FDA. Briefing document, Pharmacy Compounding Advisory Committee meeting, July 23 to 24, 2026: BPC-157-related bulk drug substances (opens in a new tab)](https://www.fda.gov/media/193343/download) 9. 9. [Sikiric P, et al. Toxicity by NSAIDs: counteraction by stable gastric pentadecapeptide BPC 157. Curr Pharm Des. 2013 (opens in a new tab)](https://pubmed.ncbi.nlm.nih.gov/22950504/) 10. 10. [NCPA. FDA grants enforcement discretion for compounding six peptides. October 29, 2026 (opens in a new tab)](https://ncpa.org/newsroom/qam/2026/10/29/fda-grants-enforcement-discretion-compounding-six-peptides) 11. 11. [FDA. Certain bulk drug substances for use in compounding that may present significant safety risks (current as of April 22, 2026) (opens in a new tab)](https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks) 12. 12. [FDA. Bulk drug substances used in compounding under section 503A (opens in a new tab)](https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act) 13. 13. [World Anti-Doping Agency. Prohibited List (opens in a new tab)](https://www.wada-ama.org/en/prohibited-list) Written by the Vitals Vault editorial team, medically reviewed by Robert Lufkin, MD, and updated October 29, 2026. This is general education, not medical advice. None of these peptides is FDA-approved to diagnose, treat, cure or prevent any disease, and compounded medicines are not FDA-reviewed for safety, effectiveness or quality. Talk to a licensed clinician before starting any treatment. --- Canonical HTML: https://www.vitalsvault.com/peptides/bpc-157 - [llms.txt](https://www.vitalsvault.com/llms.txt) - [sitemap.xml](https://www.vitalsvault.com/sitemap.xml) - [Developer portal](https://www.vitalsvault.com/developers)